Fractyl Health to Participate in the Upcoming December Conferences
GUTS 11.26.2024
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:7th Annual Evercore ISI HealthCONx Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
About Gravity Analytica
Recent News
- 01.13.2025 - Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
- 12.12.2024 - Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
- 12.09.2024 - Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Recent Filings
BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences.
Details of the presentations can be found below.
7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date: 12/03/2024
Time: 7:30 AM ET
Piper Sandler 36th Annual Healthcare Conference
Format: Fireside Chat
Date: 12/04/2024
Time: 1:30 PM ET
Webcast replays will be accessible following the live sessions on the Events page of the Investors section on the Company’s website athttps://ir.fractyl.com/.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visitwww.fractyl.com.
Contacts
Corporate ContactLisa Davidson, Chief Financial Officerir@fractyl.com, 781.902.8800
Media ContactJessica Cotrone, Corporate Communicationsjcotrone@fractyl.com, 978.760.5622
Investor ContactStephen Jasper Gilmartin Groupstephen@gilmartinir.com, 619.949.3681
